Abstract
This research underscores the substantial functions of DARS2, MRTO4, and MRPL37 in the development of BC and their potential as therapeutic targets, offering a foundation for future investigations and the development of targeted therapies.
Affiliated Institutions
Related Publications
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Abstract Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has pri...
Bladder Cancer
Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BC...
Comprehensive molecular characterization of urothelial bladder carcinoma
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved...
International Affective Picture System
Mitochondria are central to immune regulation, inflammation, and cellular metabolism. Growing evidence suggests that mitochondrial dysfunction contributes to autoimmune disease ...
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Abstract The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpres...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
Cite This
Lei Xiao,
Yujie Xiong,
Zhijie Zhuang
et al.
(2025).
Integrated multi-omics analysis identifies DARS2, MRTO4, and MRPL37 as novel biomarkers and potential therapeutic targets for bladder cancer.
Discover Oncology
.
https://doi.org/10.1007/s12672-025-04246-9
Identifiers
- DOI
- 10.1007/s12672-025-04246-9